Home

About the Initiative

7th
Framework Programme

News

Events

Contact us

Partner links

Project coordination

Other EU Projects

Project Partners Login

 

The report “Biotech in the new EU Member States: an emerging sector” is available! Click on the picture to see it:

Click on the country names to read the national reports on the state of the biotech sector:

 

Bulgaria Lithuania
Croatia Malta
Cyprus Poland
Czech Republic Romania
Estonia Slovakia
Hungary Slovenia
Latvia Turkey

 

Final policy recommendations based on the report are available here.


Press Release

Biotech needs the right policies to stay on track in new EU Member States

Brussels, 25 September 2009

EuropaBio, the European Association for Bioindustries, and Venture Valuation, with the collaboration of national stakeholders, yesterday published a ground-breaking report “Biotech in the new EU Member States: an emerging sector”, evaluating the biotech industry across the 12 newest EU Member State, as well as Turkey and Croatia.

The report identifies 260 biotechnology companies across 14 countries; and addresses the opportunities and challenges particular to each national situation. Four countries in particular, Hungary, Poland, the Czech Republic, and Estonia, report the highest numbers of biotechnology companies and were the most developed biotechnology sectors among the 14 countries analysed. One of the main challenges for the sector highlighted in the report is how to turn innovation into products when there is little guidance and support.

“Despite the political will to develop R&D as a national priority and government interest in biotechnology, concrete policies are not always put into practice.” said Patrik Frei, CEO of Venture Valuation and co-author of the report. He continued, “Setting up a coherent and consistent framework with support dedicated to the biotechnology and healthcare sectors is the key to long-term success for the industry.”

“Capacity building on intellectual property rights and patenting, as well as effective technology transfer offices are needed to stimulate commercialisation, “ said Willy De Greef, Secretary General of EuropaBio and co-author of the report. “While achievements of the sector are not yet visible in terms of products on the market, it is important to acknowledge that a solid foundation is emerging in these countries to bring about future successful developments of the biotechnology sector.”

In addition to the report, recommendations to the EU and national governments were formulated during workshops in Budapest, Prague and Vilnius, to improve the policy environment for biotechnology companies.

-ENDS-

14 AllBio Project: Policy Recommendations
Camille Burel, 14AllBio project coordinator at EuropaBio, presents policy recommendations to foster biotech development in the 12 new Member States as well as Turkey and Croatia. The 14AllBio project provided an analysis of the development of the biotech sector in the region, thereby filling the information gap compared to previous studies. For more details see the PowerPoint presentation.






Get the Facts: Biotech SMEs : Time to Act
Hear first-hand the struggle that the CEO of a biotech SME has navigating access to finance in the EU. Thomas Saylor, chair of EuropaBio's SME Platform, introduces concrete actions that need to take place for biotech SMEs to survive the financial crisis and thrive in Europe.

   


14AllBio Project - Results

Kasia Galecka from Venture Valuation presents the main findings of the 14AllBio project on the state of biotech development in the 12 new Member States as well as Turkey and Croatia. The 14AllBio project provided an analysis of the development of the biotech sector in the region, thereby filling the information gap compared to previous studies. For more details, see the PowerPoint presentation





EuropaBio • Avenue de l'Armée 6 • 1040 Brussels • Belgium • Tel : (+32.2) 735.03.13 • Fax : (+32.2) 735.49.60 • info@europabio.org